Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
J Clin Lab Anal. 2022 Oct;36(10):e24670. doi: 10.1002/jcla.24670. Epub 2022 Aug 21.
Circular RNAs (circRNAs) play pivotal roles in proliferation, apoptosis, migration, and invasion of renal cell carcinoma (RCC) cells. This study is aimed to systematically summarize the current evidence regarding the clinical implications of circRNAs in RCC patients.
A systematic search in PubMed, Embase, and Web of Science was performed until January 1, 2022. The correlation between the expression of circRNAs and clinicopathological, prognostic, and diagnostic features of RCC was evaluated using the meta-analysis.
Ultimately, 41 studies with 3485 RCC patients were included in this study: 26 studies for clinicopathological features, 31 studies for prognosis, and eight studies for diagnosis. Altered expression of circRNAs was significantly associated with clinicopathological characteristics of RCC, including tumor size, tumor stage, lymph node metastasis, distant metastasis, and TNM stage. The tumor promoter circRNAs were associated with reduced overall survival (OS) (Hazard Ratio (HR) = 1.98, 95% confidence interval [CI] 1.68-2.34) and disease/progression/recurrence-free survival (DFS/PFS/RFS) (HR = 2.34, 95% CI 1.85-2.97). Contrarily, the tumor suppressor circRNAs were linked with better OS (HR = 0.49, 95% CI 0.40-0.60) and DFS/PFS/RFS (HR = 0.40, 95% CI 0.28-0.59). The pooled sensitivity and specificity of circRNAs for RCC diagnosis in tissue samples were both 0.84. These results in fluid samples (serum and urine) were 0.78 and 0.69, respectively.
CircRNAs can serve as promising diagnostic and prognostic biomarkers for RCC.
环状 RNA（circRNA）在肾细胞癌（RCC）细胞的增殖、凋亡、迁移和侵袭中发挥关键作用。本研究旨在系统总结 circRNA 在 RCC 患者中的临床意义的现有证据。
在 PubMed、Embase 和 Web of Science 上进行了系统检索，截至 2022 年 1 月 1 日。使用荟萃分析评估 circRNA 的表达与 RCC 的临床病理、预后和诊断特征之间的相关性。
最终，本研究纳入了 41 项研究，共 3485 例 RCC 患者：26 项研究用于临床病理特征，31 项研究用于预后，8 项研究用于诊断。circRNA 的表达改变与 RCC 的临床病理特征显著相关，包括肿瘤大小、肿瘤分期、淋巴结转移、远处转移和 TNM 分期。肿瘤促进 circRNA 与总生存期（OS）降低相关（风险比（HR）=1.98，95%置信区间 [CI] 1.68-2.34）和疾病/进展/无复发生存期（DFS/PFS/RFS）（HR=2.34，95%CI 1.85-2.97）。相反，肿瘤抑制 circRNA 与更好的 OS（HR=0.49，95%CI 0.40-0.60）和 DFS/PFS/RFS（HR=0.40，95%CI 0.28-0.59）相关。circRNA 用于组织样本中 RCC 诊断的汇总敏感性和特异性均为 0.84。在液体样本（血清和尿液）中的结果分别为 0.78 和 0.69。
circRNA 可以作为 RCC 有前途的诊断和预后生物标志物。
